KA2507, a potent, orally active and selective HDAC6 inhibitor with IC50 of 2.5 nM, shows antitumor activities and immune modulatory effects in preclinical models.
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
KA2507, a potent, orally active and selective HDAC6 inhibitor with IC50 of 2.5 nM, shows antitumor activities and immune modulatory effects in preclinical models.
[1] Tsimberidou AM, et al. Clin Cancer Res. 2021 Jul 1;27(13):3584-3594.